RxDoctor Payments Data

Randy Rizor, MD

Interventional Pain Medicine · Sandy Springs, GANPI 1245204882

Payments from drug & device makers

$1,478in general payments, 2019–2025

Across 66 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$359
  • Abbott$193
  • Pacira Pharmaceuticals Incorporated$102
  • AbbVie$96
  • Arbor Pharmaceuticals, Inc.$90
  • Nevro Corp.$75
  • plus $564 from 22 others

What the payments were for

  • Food & beverage$1,23984%
  • Education$24016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,478 in reported general payments places this provider in the 30th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$101,153
Medicare patients
200
Services billed
2,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl32$20,545
Xtampza ErOxycodone Myristate34$17,917
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen505$11,409
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen396$11,135
Oxycodone Hcl229$3,855
Morphine Sulfate ErMorphine Sulfate69$2,426
Fentanyl40$2,184
Lidocaine19$2,164
Gabapentin102$1,892
Tramadol Hcl67$802
Duloxetine Hcl66$786
Diclofenac Sodium43$674
Hydromorphone Hcl29$465
Tizanidine Hcl40$415
Celecoxib23$303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$45$17,91734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 129 interventional pain medicine providers in Georgia.

Other interventional pain medicine in Sandy Springs

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →